Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Western Union Co — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Western Union Co trades at $6.32 (market cap $1.91B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 67.1× Western Union Co's market cap, and Western Union Co pays a 15.38% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Western Union Co for 95 Days on average.
| VRTX | WU | |
|---|---|---|
Market Cap | $128.16B | $1.91B |
Volume | 806,603 | 6,459,194 |
Sector | Health | Financials |
52-Week High | $557.96 | $10.28 |
52-Week Low | $407.37 | $5.90 |
Typical Hold Time | 120 Days | 95 Days |
Enterprise Value | $122.29B | $1.81B |
Dividend Yield | — | 15.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Western Union (WU) trades at $6.33, up 3.09% with bearish technical signals but attractive valuation metrics including a P/E of 4.93 and P/S of 0.48. Recent earnings show mixed performance with two misses in the last three quarters, while the company maintains strong profitability with 9.79% net margin and 43.97% ROE. The $200 million Beyond Efficiency Plan and pending Intermex acquisition represent key strategic initiatives amid declining revenue trends from $4.5B in 2022 to $4.0B projected for 2026.
WU presents a value opportunity with deep valuation discounts but faces significant headwinds including revenue contraction and integration risks from the Intermex acquisition. Analyst sentiment remains cautious with only 12% buy ratings, though the $6.86 consensus target offers 8% upside. The stock's appeal hinges on successful cost-cutting execution and digital transformation amid competitive pressures in money transfer services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
